p12CDK2AP1 Regulation of Normal and Neoplastic Growth

p12CDK2AP1 正常和肿瘤生长的调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): The proposed plan for this NCI Mentored Career Development for Underrepresented Minorities K01 award is a two-year Mentored Phase, followed by a three-year Independent Phase. The Mentored Phase will provide for advanced training for the minority principal investigator under the co-mentorship of Dr. David Wong at the Laboratory of Head and Neck Cancer Research/Dental Research Institute and Dr. Lily Wu at the Vector-based Gene Therapy Laboratory/Crump Institute for Molecular Imaging at UCLA. This phase will provide the candidate with the opportunity to focus her efforts on research and development towards an academic career as an independent scientist. The overall goal of this proposal is to examine the role of p12 CDK2AP11 in regulating normal and neoplastic growth using in vivo model systems. Our rationale is that p12CDK2AP1, a cell cycle regulator and CDK2-associating protein commonly downregulated in -70% of head and neck cancers, is importantly involved in regulating normal and neoplastic growth in vivo. Several studies have shown that reexpressing p12 CDK2AP1 in tumor cells results in growth inhibition and induction of apoptosis, however little is known regarding the role of this molecule in regulating normal cell growth. During the Mentored Phase, the candidate will engage in investigating the role of pi2 CDK2AP1in normal development, and generating novel p12 CDK2AP1-based gene therapies for head and neck cancer treatment. In addition to the research training, a didactic component has been incorporated in the career development plan to enhance the candidate's overall career development. Defined milestones also will be in place to assess the candidate's scientific progress, particularly during transition to the Independent Phase. During the Independent Phase, the candidate will engage in examining the role of p12 CDK2AP1 in neoplastic growth by temporally ablating p12 CDK2AP1 expression specifically in adult head and neck tissues and developing novel tumor-targeted gene therapy strategies for future translational applications. The examination of the cellular and molecular responses to p12 CDK2AP1 ablation and therapy will provide insights into the functions of this cell cycle regulator in normal and neoplastic growth in vivo. This K01 mechanism is critical in assuring the time and resources needed for the development of the candidate into an independent research scientist in the field of cancer biology.
说明(由申请人提供): NCI 针对代表性不足的少数族裔 K01 指导职业发展奖的拟议计划是一个为期两年的指导阶段,随后是一个为期三年的独立阶段。指导阶段将在头颈癌研究实验室/牙科研究所的 David Wong 博士和加州大学洛杉矶分校基于载体的基因治疗实验室/克伦普分子成像研究所的 Lily Wu 博士的共同指导下,为少数派首席研究员提供高级培训。这一阶段将为候选人提供将精力集中在研究和开发上的机会,以实现作为独立科学家的学术生涯。该提案的总体目标是使用体内模型系统检查 p12 CDK2AP11 在调节正常和肿瘤生长中的作用。我们的理由是,p12CDK2AP1(一种细胞周期调节剂和 CDK2 相关蛋白,在 -70% 的头颈癌中通常下调)在调节体内正常和肿瘤生长方面发挥着重要作用。多项研究表明,在肿瘤细胞中重新表达 p12 CDK2AP1 会导致生长抑制和诱导细胞凋亡,但对该分子在调节正常细胞生长中的作用知之甚少。在指导阶段,候选人将参与研究 pi2 CDK2AP1 在正常发育中的作用,并产生用于头颈癌治疗的新型基于 p12 CDK2AP1 的基因疗法。除了研究培训之外,职业发展计划中还纳入了教学部分,以促进候选人的整体职业发展。还将制定明确的里程碑来评估候选人的科学进展,特别是在向独立阶段过渡期间。在独立阶段,候选人将通过暂时消除成人头颈组织中的 p12 CDK2AP1 表达,并为未来的转化应用开发新型肿瘤靶向基因治疗策略,来研究 p12 CDK2AP1 在肿瘤生长中的作用。对 p12 CDK2AP1 消融和治疗的细胞和分子反应的检查将深入了解该细胞周期调节剂在体内正常和肿瘤生长中的功能。这种K01机制对于确保候选人发展成为癌症生物学领域的独立研究科学家所需的时间和资源至关重要。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Novel tumor growth inhibition mechanism by cell cycle regulator cdk2ap1 involves antiangiogenesis modulation.
  • DOI:
    10.1016/j.mvr.2010.06.001
  • 发表时间:
    2010-12
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    Zolochevska O;Figueiredo ML
  • 通讯作者:
    Figueiredo ML
Expression of cell cycle regulator cdk2ap1 suppresses tumor cell phenotype by non-cell-autonomous mechanisms.
  • DOI:
    10.1016/j.oraloncology.2009.05.001
  • 发表时间:
    2009-09
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Zolochevska, Olga;Figueiredo, Marxa L.
  • 通讯作者:
    Figueiredo, Marxa L.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marxa L Figueiredo其他文献

Marxa L Figueiredo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marxa L Figueiredo', 18)}}的其他基金

Facilitating Endogenous Bone Repair in Arthritis with Targeted IL-27 Sonodelivery
通过靶向 IL-27 声波传递促进关节炎的内源性骨修复
  • 批准号:
    10352199
  • 财政年份:
    2018
  • 资助金额:
    $ 9.98万
  • 项目类别:
Facilitating Endogenous Bone Repair in Arthritis with Targeted IL-27 Sonodelivery
通过靶向 IL-27 声波传递促进关节炎的内源性骨修复
  • 批准号:
    10088413
  • 财政年份:
    2018
  • 资助金额:
    $ 9.98万
  • 项目类别:
Disrupting tumor/bone malignant interactions with multifunctional cytokine sonodelivery
通过多功能细胞因子超声传递破坏肿瘤/骨恶性相互作用
  • 批准号:
    9894745
  • 财政年份:
    2016
  • 资助金额:
    $ 9.98万
  • 项目类别:
Disrupting tumor/bone malignant interactions with multifunctional cytokine sonodelivery
通过多功能细胞因子超声传递破坏肿瘤/骨恶性相互作用
  • 批准号:
    9262887
  • 财政年份:
    2016
  • 资助金额:
    $ 9.98万
  • 项目类别:
Pro-peptide gene delivery for treating prostate cancer bone metastases
用于治疗前列腺癌骨转移的前肽基因递送
  • 批准号:
    8681404
  • 财政年份:
    2013
  • 资助金额:
    $ 9.98万
  • 项目类别:
Pro-peptide gene delivery for treating prostate cancer bone metastases
用于治疗前列腺癌骨转移的前肽基因递送
  • 批准号:
    8585630
  • 财政年份:
    2013
  • 资助金额:
    $ 9.98万
  • 项目类别:
Preventing prostate cancer progression by ASC delivery of PEDF and IFNb
通过 ASC 输送 PEDF 和 IFNb 预防前列腺癌进展
  • 批准号:
    8446315
  • 财政年份:
    2012
  • 资助金额:
    $ 9.98万
  • 项目类别:
Preventing prostate cancer progression by ASC delivery of PEDF and IFNb
通过 ASC 输送 PEDF 和 IFNb 预防前列腺癌进展
  • 批准号:
    8289223
  • 财政年份:
    2012
  • 资助金额:
    $ 9.98万
  • 项目类别:
Preventing prostate cancer progression by ASC delivery of PEDF and IFNb
通过 ASC 输送 PEDF 和 IFNb 预防前列腺癌进展
  • 批准号:
    8700570
  • 财政年份:
    2012
  • 资助金额:
    $ 9.98万
  • 项目类别:
MECHANISMS OF XMRV ONCOGENESIS IN PROSTATE CELLS
XMRV 在前列腺细胞中的致癌机制
  • 批准号:
    8359781
  • 财政年份:
    2011
  • 资助金额:
    $ 9.98万
  • 项目类别:

相似海外基金

Monitoring the Regulation of Mitophagy in Skeletal Muscles Under Normal and Pathological Conditions
正常和病理条件下监测骨骼肌线粒体自噬的调节
  • 批准号:
    495297
  • 财政年份:
    2023
  • 资助金额:
    $ 9.98万
  • 项目类别:
Epigenetic regulation of keratinocyte function in normal and pathologic skin repair
正常和病理性皮肤修复中角质形成细胞功能的表观遗传调控
  • 批准号:
    10677308
  • 财政年份:
    2023
  • 资助金额:
    $ 9.98万
  • 项目类别:
Regulation of myocardial GPCRs by USP20 in normal and hypertrophied heart
USP20 对正常和肥厚心脏中心肌 GPCR 的调节
  • 批准号:
    10427441
  • 财政年份:
    2021
  • 资助金额:
    $ 9.98万
  • 项目类别:
Regulation of hemoglobin production in normal and disease states
正常和疾病状态下血红蛋白产生的调节
  • 批准号:
    10405498
  • 财政年份:
    2021
  • 资助金额:
    $ 9.98万
  • 项目类别:
Regulation of myocardial GPCRs by USP20 in normal and hypertrophied heart
USP20 对正常和肥厚心脏中心肌 GPCR 的调节
  • 批准号:
    10317884
  • 财政年份:
    2021
  • 资助金额:
    $ 9.98万
  • 项目类别:
Regulation of myocardial GPCRs by USP20 in normal and hypertrophied heart
USP20 对正常和肥厚心脏中心肌 GPCR 的调节
  • 批准号:
    10630331
  • 财政年份:
    2021
  • 资助金额:
    $ 9.98万
  • 项目类别:
Regulation of hemoglobin production in normal and disease states
正常和疾病状态下血红蛋白产生的调节
  • 批准号:
    10612921
  • 财政年份:
    2021
  • 资助金额:
    $ 9.98万
  • 项目类别:
Regulation of hemoglobin production in normal and disease states
正常和疾病状态下血红蛋白产生的调节
  • 批准号:
    10189076
  • 财政年份:
    2021
  • 资助金额:
    $ 9.98万
  • 项目类别:
Role of TAZ in metabolic regulation in both normal and insulin resistant states
TAZ 在正常和胰岛素抵抗状态下代谢调节中的作用
  • 批准号:
    10314061
  • 财政年份:
    2020
  • 资助金额:
    $ 9.98万
  • 项目类别:
Role of TAZ in metabolic regulation in both normal and insulin resistant states
TAZ 在正常和胰岛素抵抗状态下代谢调节中的作用
  • 批准号:
    10526415
  • 财政年份:
    2020
  • 资助金额:
    $ 9.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了